PA8773501A1 - Inhibidores de canales de iones - Google Patents

Inhibidores de canales de iones

Info

Publication number
PA8773501A1
PA8773501A1 PA20088773501A PA8773501A PA8773501A1 PA 8773501 A1 PA8773501 A1 PA 8773501A1 PA 20088773501 A PA20088773501 A PA 20088773501A PA 8773501 A PA8773501 A PA 8773501A PA 8773501 A1 PA8773501 A1 PA 8773501A1
Authority
PA
Panama
Prior art keywords
compositions
compounds
procedures
inhibition
treatment
Prior art date
Application number
PA20088773501A
Other languages
English (en)
Spanish (es)
Inventor
Alan Swain Nigel
Edward Marron Brian
Christopher Fritch Paul
John Markworth Christopher
Thomas Maynard Andrew
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PA8773501A1 publication Critical patent/PA8773501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/42—Benzene-sulfonamido pyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
PA20088773501A 2007-03-23 2008-03-24 Inhibidores de canales de iones PA8773501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89673507P 2007-03-23 2007-03-23
US3532408P 2008-03-10 2008-03-10

Publications (1)

Publication Number Publication Date
PA8773501A1 true PA8773501A1 (es) 2009-04-23

Family

ID=39788940

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088773501A PA8773501A1 (es) 2007-03-23 2008-03-24 Inhibidores de canales de iones

Country Status (14)

Country Link
US (2) US8357711B2 (enExample)
EP (1) EP1995241B1 (enExample)
JP (1) JP5361857B2 (enExample)
AR (1) AR065824A1 (enExample)
AT (1) ATE461177T1 (enExample)
CA (1) CA2681572C (enExample)
CL (1) CL2008000835A1 (enExample)
DE (1) DE602008000809D1 (enExample)
ES (1) ES2340640T3 (enExample)
PA (1) PA8773501A1 (enExample)
PE (1) PE20090237A1 (enExample)
TW (1) TW200845969A (enExample)
UY (1) UY30978A1 (enExample)
WO (1) WO2008118758A1 (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023272A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
PT2197849E (pt) * 2007-10-09 2013-04-23 Merck Patent Gmbh Derivados de n-(pirazole-3-il)-benzamida como ativadores de glucoquinase
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
WO2010033824A1 (en) * 2008-09-19 2010-03-25 Icagen, Inc. Sulfonamide derivatives as inhibitors of ion channels
WO2010035166A1 (en) * 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
JP2012506376A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換モルホリンオレキシン受容体アンタゴニスト
HRP20150355T1 (hr) * 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
CN102427810A (zh) * 2009-05-01 2012-04-25 拉夸里亚创药株式会社 作为trpm8拮抗剂的氨磺酰基苯甲酸衍生物
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
BR112012009574A2 (pt) * 2009-10-22 2019-09-24 Univ Vanderbilt potencializador alostérico de mglura, composições, e métodos de tratamento de disfunção neurológica
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
WO2011104649A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues
EA201201289A1 (ru) * 2010-03-16 2013-08-30 Мерк Патент Гмбх Морфолинилхиназолины
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
EP2590957B1 (en) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2813708C (en) * 2010-10-18 2019-09-17 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
AP2013007159A0 (en) 2011-04-05 2013-10-31 Pfizer Ltd Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
US8957025B2 (en) 2011-07-13 2015-02-17 Pfizer Inc. Enkephalin analogues
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
US9079878B2 (en) 2011-10-26 2015-07-14 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
EP2771325B1 (en) 2011-10-28 2017-06-28 Inhibitaxin Limited Pyridazine derivatives useful in therapy
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9085517B2 (en) 2011-12-15 2015-07-21 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
JP6067031B2 (ja) 2012-01-04 2017-01-25 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アミノスルホニルベンズアミド
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
US9701658B2 (en) 2012-04-25 2017-07-11 Raqualia Pharma Inc. Amide derivatives as TTX-S blockers
KR101719893B1 (ko) 2012-05-22 2017-03-24 제넨테크, 인크. Ｎ-치환된 벤즈아미드 및 통증의 치료에서 이들의 용도
JP6309519B2 (ja) 2012-07-06 2018-04-11 ジェネンテック， インコーポレイテッド Ｎ置換ベンズアミド及びその使用方法
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
EP2903989A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
JP2015531393A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
ES2828503T3 (es) 2012-10-15 2021-05-26 Dae Woong Pharma Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
EP2988748A1 (en) * 2013-04-23 2016-03-02 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3083602A1 (en) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
EP3131891A1 (en) 2014-04-15 2017-02-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
CA2950393A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
JP6491679B2 (ja) 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
MX386501B (es) 2015-09-28 2025-03-19 Genentech Inc Compuestos terapeuticos y sus metodos de uso
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
JP2018536677A (ja) 2015-12-10 2018-12-13 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ てんかんおよび疼痛の治療において使用するための、ＧＡＢＡ受容体モジュレーターとしての式（Ｉ）の４−（ビフェン−３−イル）−１Ｈ−ピラゾロ［３，４−ｃ］ピリダジン誘導体
JP2019502688A (ja) * 2015-12-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 電位作動型ナトリウムチャネルにおいて選択的活性を有するジアミノ−アルキルアミノ結合アリールスルホンアミド化合物
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2019532077A (ja) 2016-10-17 2019-11-07 ジェネンテック， インコーポレイテッド 治療用化合物及びその使用方法
US11046683B2 (en) 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
WO2018132550A1 (en) 2017-01-11 2018-07-19 The General Hospital Corporation Voltage gated sodium channel imaging agents
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
CN110740915B (zh) * 2017-06-27 2022-11-15 本田技研工业株式会社 行驶控制系统以及车辆的控制方法
MX2020002147A (es) * 2017-08-25 2022-10-03 The Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College Composiciones útiles para la mejora del dolor.
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN108752274B (zh) * 2018-07-25 2022-03-29 遂成药业股份有限公司 一种5-异喹啉磺酰氯的制备方法
JP7692834B2 (ja) 2019-03-11 2025-06-16 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
BR112021017809A2 (pt) 2019-03-11 2021-11-23 Nocion Therapeutics Inc Bloqueadores de canais iônicos substituídos por éster e métodos para uso
BR112021017772A2 (pt) 2019-03-11 2021-11-16 Nocion Therapeutics Inc Bloqueadores de canais de íons carregados e métodos para uso
AU2020380118A1 (en) 2019-11-06 2022-05-19 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP7513713B2 (ja) 2019-11-06 2024-07-09 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
BR112022017801A2 (pt) 2020-03-11 2022-10-25 Nocion Therapeutics Inc Bloqueadores de canais de íons carregados e métodos para uso
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
AU2022270061A1 (en) * 2021-05-07 2023-11-16 Merck Sharp & Dohme Llc Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CN115015310B (zh) * 2022-05-23 2024-12-10 宁波大学 一种巯基化合物的分析方法
KR20240172702A (ko) * 2023-05-30 2024-12-10 삼진제약주식회사 신규한 벤즈아미드 유도체 화합물 및 이를 포함하는 약학적 조성물
WO2025137437A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Solid forms of a gabaa receptor modulator and methods of its use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US6673824B1 (en) 1992-05-06 2004-01-06 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
DE69719766T2 (de) 1996-08-29 2004-01-15 Takeda Chemical Industries Ltd Zyklische etherverbindungen als natriumkanal-modulatoren
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
GB9800750D0 (en) * 1998-01-14 1998-03-11 Lilly Co Eli Pharmaceutical compound
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
US6586475B1 (en) 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
WO2000053573A1 (en) 1999-03-10 2000-09-14 Shionogi & Co., Ltd. Medicinal compositions with [2.2.1] and [3.1.1] bicycloskeleton antagonistic to both of pgd2/txa2 receptors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
WO2001016094A1 (de) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2001049289A1 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
IL150311A0 (en) 1999-12-31 2002-12-01 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2001070734A2 (en) 2000-03-17 2001-09-27 Bristol-Myers Squibb Pharma Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
US20040110743A1 (en) 2000-05-19 2004-06-10 Masaomi Miyamato -Secretase inhibitors
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001270029A1 (en) 2000-06-21 2002-01-02 Smith Kline Beecham Corporation Macrophage scavenger receptor antagonists
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CA2466490C (en) 2001-11-22 2009-12-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04004837A (es) 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
JP2003292485A (ja) * 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
AU2003226929A1 (en) 2002-11-25 2004-06-18 7Tm Pharma A/S Novel benzamide compounds for use in mch receptor related disorders
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
BRPI0409949A (pt) 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
FR2856133B1 (fr) 2003-06-16 2005-11-04 Commissariat Energie Atomique Dispositif d'exploration de canalisations avec tete centree
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
SE0301886D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use V
SE0301888D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use VII
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US7538135B2 (en) 2003-07-08 2009-05-26 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
TW200524888A (en) 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
WO2006060762A2 (en) 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
JP2009514858A (ja) 2005-11-03 2009-04-09 メルク エンド カムパニー インコーポレーテッド アリール−ピラゾリルモチーフを有するヒストンデアセチラーゼ阻害剤
AU2007238897A1 (en) 2006-04-12 2007-10-25 Wyeth Anilino-pyrimidine phenyl and benzothiophene analogs

Also Published As

Publication number Publication date
WO2008118758A1 (en) 2008-10-02
US20090143358A1 (en) 2009-06-04
JP2010522242A (ja) 2010-07-01
JP5361857B2 (ja) 2013-12-04
EP1995241B1 (en) 2010-03-17
CL2008000835A1 (es) 2008-10-03
EP1995241A1 (en) 2008-11-26
PE20090237A1 (es) 2009-03-29
ATE461177T1 (de) 2010-04-15
DE602008000809D1 (de) 2010-04-29
ES2340640T3 (es) 2010-06-07
UY30978A1 (es) 2008-10-31
US20130072471A1 (en) 2013-03-21
CA2681572C (en) 2014-02-11
US8357711B2 (en) 2013-01-22
TW200845969A (en) 2008-12-01
US8741934B2 (en) 2014-06-03
CA2681572A1 (en) 2008-10-02
AR065824A1 (es) 2009-07-01

Similar Documents

Publication Publication Date Title
PA8773501A1 (es) Inhibidores de canales de iones
MX351028B (es) Determinadadas entidades, composiciones y metodos quimicos.
HN2008001464A (es) Formulaciones para administrcion parenteral de compuestos y sus usos
CL2018002924A1 (es) Inhibidores de bromodominios
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
UY30098A1 (es) Compuestos de tiazol y metodos de uso
ECSP16025201A (es) Profármacos de amidas de piridona útiles como moduladores de canales de sodio
MA31564B1 (fr) Inhibition par arni de l'expression du canal alpha-enac
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
PA8842101A1 (es) Heteroarilos sustituidos
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
MX359882B (es) Amidas como moduladores de canales de sodio.
HN2008001532A (es) Derivados de dihidropirazolopirimidina
HN2011000193A (es) Derivados de piridazina como inhibidores de smo
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
CO6210786A2 (es) Implemento de cuidado oral que alberga un agente de cuidado oral
CR8879A (es) Bifeniltiazolcarboxamidas
HN2009001282A (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
AR113211A2 (es) Derivados de bencilfenilciclohexano y métodos de uso
CR11285A (es) Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma